Castle Biosciences (NASDAQ:CSTL) COO Kristen Oelschlager Sells 12,218 Shares

Castle Biosciences, Inc. (NASDAQ:CSTL) COO Kristen Oelschlager sold 12,218 shares of Castle Biosciences stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $33.69, for a total value of $411,624.42. Following the completion of the transaction, the chief operating officer owned 85,033 shares of the company’s stock, valued at approximately $2,864,761.77. The trade was a 12.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Castle Biosciences Stock Performance

CSTL stock opened at $34.08 on Thursday. The company has a current ratio of 6.04, a quick ratio of 5.85 and a debt-to-equity ratio of 0.02. The firm has a market cap of $1.04 billion, a P/E ratio of -51.64 and a beta of 0.98. Castle Biosciences, Inc. has a 12-month low of $17.72 and a 12-month high of $44.28. The stock’s 50 day simple moving average is $26.73 and its 200 day simple moving average is $25.41.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.34. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%.The firm had revenue of $99.86 million for the quarter, compared to analysts’ expectations of $86.23 million. As a group, equities research analysts predict that Castle Biosciences, Inc. will post -1.29 EPS for the current year.

Analysts Set New Price Targets

CSTL has been the subject of a number of recent research reports. Roth Capital initiated coverage on shares of Castle Biosciences in a research report on Wednesday, June 24th. They set a “buy” rating and a $40.00 price objective for the company. BTIG Research lifted their target price on Castle Biosciences from $40.00 to $44.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Wall Street Zen raised Castle Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. Robert W. Baird set a $36.00 price target on Castle Biosciences in a research report on Friday, July 31st. Finally, Zacks Research downgraded Castle Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 26th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $42.00.

Institutional Trading of Castle Biosciences

A number of large investors have recently modified their holdings of CSTL. BlackRock Inc. bought a new stake in Castle Biosciences in the 2nd quarter valued at about $78,513,000. Vanguard Group Inc. grew its position in Castle Biosciences by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 2,199,829 shares of the company’s stock worth $85,573,000 after purchasing an additional 27,511 shares during the last quarter. RTW Investments LP acquired a new stake in shares of Castle Biosciences in the fourth quarter valued at approximately $82,283,000. Principal Financial Group Inc. increased its stake in shares of Castle Biosciences by 0.7% in the fourth quarter. Principal Financial Group Inc. now owns 1,807,644 shares of the company’s stock valued at $70,317,000 after purchasing an additional 13,289 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Castle Biosciences by 7.0% during the third quarter. Dimensional Fund Advisors LP now owns 1,474,089 shares of the company’s stock valued at $33,564,000 after buying an additional 96,084 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.